Latest News and Press Releases

Dublin, April 08, 2025 (GLOBE NEWSWIRE) -- The "Antidepressant Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ...

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Postpartum Depression - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering "Postpartum Depression - Pipeline...

Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Anxiety Disorders and Depression Treatment Global Market Report, Forecast by Product, Indication, Country and Company Analysis 2024-2032" report has...

London, Feb. 07, 2024 (GLOBE NEWSWIRE) -- An international clinical trial which is investigating a novel synthetic formulation of the psychedelic substance 5-MeO-DMT (also known as Mebufotenin) for...

NEWARK, Del, Dec. 16, 2022 (GLOBE NEWSWIRE) -- The global Treatment-Resistant Depression Therapeutics Market is experiencing rapid growth as the prevalence of depression and anxiety disorders...

NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...

GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD completed enrollment and on track for readout of topline results by year-end 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD to conclude patient...

First patient enrolled in placebo-controlled GEMINI study Topline results anticipated in 2H 2019 NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...

Previously completed active-controlled ASCEND trial in MDD now considered as pivotal; sufficient with ongoing STRIDE-1 Phase 3 trial for NDA in MDD Target randomization for STRIDE-1 Phase 3 trial...

Demonstrated statistically significant improvement in MADRS scores compared to active comparator (p<0.001 on primary endpoint) Rapid improvement in depressive symptoms demonstrating statistically...